---
title: "Incyte falls on weak annual forecast for skin disorder drug"
date: "2025-02-11 00:19:49"
summary: "** Drugmaker Incyte Corp's shares fall 7.2% to $68.8** Co expects 2025 sales of skin-disorder drug Opzelura to be between $630 million and $670 million, below analysts' estimates of $671 million - data compiled by LSEG ** Brokerage BMO Capital Markets says the downbeat forecast potentially suggests a slowing of..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* Drugmaker Incyte Corp's shares fall 7.2% to $68.8

\*\* Co expects 2025 sales of skin-disorder drug Opzelura to be between $630 million and $670 million, below analysts' estimates of $671 million - data compiled by LSEG

\*\* Brokerage BMO Capital Markets says the downbeat forecast potentially suggests a slowing of revenue expansion in vitiligo

\*\* Vitiligo is a chronic autoimmune disorder that causes white patches to appear on the skin

\*\* Q4 sales of Opzelura came in at $161.6 million, beating estimates of $149.9 million

\*\* Q4 sales of blood-cancer drug Jakafi rose 11% to $773.1 million vs estimates of $744.9 million

\*\* Co sees annual sales for Jakafi of $2.93 bln to $2.98 bln, above estimates of $2.93 bln

\*\* Stock rose 5.5% in 2024

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P115K:0-incyte-falls-on-weak-annual-forecast-for-skin-disorder-drug/)
